BRIAN RESNICK: Open Payments
NPI 1144305012 · TELFORD, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$546 in 26 payments from 11 companies in 2025. Trend: 2023 $859 · 2024 $527 · 2025 $546
Food & beverage: $546
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 9 | $205 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 3 | $55 |
| AstraZeneca Pharmaceuticals LP | 3 | $55 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $51 |
| Lilly USA, LLC | 2 | $40 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 2 | $40 |
| REVANCE THERAPEUTICS, INC. | 1 | $22 |
| GlaxoSmithKline, LLC. | 1 | $22 |
| ABBVIE INC. | 1 | $19 |
| Galderma Laboratories, L.P. | 1 | $18 |
Products named: Rybelsus, XIFAXAN, Kerendia, MOUNJARO, JARDIANCE, AIRSUPRA, Ozempic, DAXXIFY.
Industry payments across PA — which companies pay providers there.
